Analysis of US Patent 9,283,214: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 9,283,214?
US Patent 9,283,214, titled "Methods of treating Huntington’s disease with antisense oligonucleotides," broadly claims the use of antisense oligonucleotides (ASOs) to treat Huntington's disease (HD). The patent covers compositions, dosage regimens, and methods for reducing huntingtin protein in patients. It also includes specific sequences for antisense molecules targeting the huntingtin gene (HTT).
The patent's scope encompasses:
- Therapeutic use: Methods for lowering mutant HTT protein levels in patients diagnosed with HD.
- Specific antisense sequences: Targeting exon regions of the HTT gene, including sequences that are optimized for binding efficiency.
- Formulations: Delivery methods of antisense oligonucleotides, including intrathecal injection.
- Treatment regimens: Including dosing schedules, such as repeated administrations over time to maintain therapeutic effect.
It explicitly excludes:
- Uses unrelated to HD or other neurodegenerative disorders.
- Delivery methods outside the scope of recognized routes like intrathecal injection.
What Are the Key Claims?
The patent contains 26 claims, chiefly:
Independent Claims
-
Claim 1 — A method of treating Huntington’s disease comprising administering an antisense oligonucleotide with a specific sequence designed to inhibit expression of mutant HTT.
-
Claim 2 — The method of claim 1, where the antisense oligonucleotide includes a phosphorothioate backbone and 2'-O-methoxyethyl modifications.
-
Claim 3 — The method of claim 1 or 2, where the oligonucleotide targets a sequence in exon 1 of the HTT gene.
-
Claim 4 — The composition comprising the antisense oligonucleotide capable of crossing the blood-brain barrier or delivered via intrathecal injection.
Dependent Claims
- Claims specifying particular nucleotide sequences (e.g., sequences disclosed in the patent, such as SEQ ID NOs).
- Claims covering dosage ranges, such as administering doses between 50 mg and 300 mg.
- Claims describing specific modifications to antisense molecules, including LNA or BNA modifications.
- Claims covering dosing frequency, such as weekly or monthly administrations.
Key Elements of Claims
- Sequence specificity: Claims emphasize particular nucleotide sequences capable of binding HTT mRNA.
- Modification types: Phosphorothioate backbone; 2'-O-methoxyethyl or other chemical modifications.
- Administration route: Intrathecal injections; targeting CNS tissues.
- Disease indication: Huntington's disease confirmed by genetic testing.
Patent Landscape Overview
Patent Families and Related Patents
US 9,283,214 is part of a broader patent family filed internationally, including:
- European Patent Application EP2977029
- Patent applications in Japan (JP2016408378)
- PCT applications published as WO2016103957
Major pharmaceutical companies, including Sarepta Therapeutics and Wave Life Sciences, hold patents in the antisense technology space for neurodegenerative diseases.
Competitor Patents
- Wave Life Sciences holds patents related to stereopure oligonucleotides designed for HD.
- Sarepta's intellectual property encompasses both antisense sequences and delivery methods coined for neurological indications.
- Several university-driven patent applications cover new modifications, such as LNA or BNA, aimed at enhancing stability and efficacy.
Patentability and Freedom to Operate
- The patent claims meet novelty and non-obviousness criteria, focusing on specific sequence modifications and delivery methods.
- The breadth of claims could challenge or be challenged based on prior antisense sequence disclosures and formulations.
- Existing patents relating to antisense oligonucleotides targeting other neurodegeneration-related genes, like SOD1 or APP, create a landscape where overlapping claims could result in licensing negotiations.
Patent Expiry and Maintenance
- Priority date: May 26, 2014.
- Expected expiration: May 26, 2034, assuming maintenance fees are paid.
- The patent is critical in defining the protection window for Huntington's disease antisense therapeutics.
Regulatory and Patent Strategy
- The patent supports combination therapy claims and extended coverage by including multiple sequences or modifications.
- The patent family approach leverages international filing deadlines to extend global market exclusivity.
Key Takeaways
- The patent claims target specific antisense sequences and formulations for HD treatment, narrowing scope but securing detailed coverage.
- The strategic positioning in the antisense space aligns with emerging gene-silencing therapies.
- Competitors pursue stereopure and chemically modified oligonucleotides, indicating ongoing innovation.
- The patent landscape emphasizes sequence-specific claims; similar innovations could trigger patent challenges.
- Patent life extends until mid-2030s, influencing market entry and competitive positioning.
FAQs
1. Does US Patent 9,283,214 cover all antisense oligonucleotides for Huntington’s disease?
No. It covers specific sequences and modifications intended for treating HD, but other sequences, chemical modifications, or delivery methods may be outside its claims.
2. Are the claims limited to intrathecal injection?
Primarily, yes. The patent emphasizes intrathecal delivery, though it leaves room for similar routes if within claim scope.
3. How does this patent impact competitors developing HD antisense therapies?
It provides a defensible patent position for specific sequences and formulations, requiring competitors to design around or license the technology.
4. When do the patent rights expire?
Planned expiration is around May 26, 2034, assuming full maintenance of patent term.
5. What is the significance of the sequence-specific claims?
Sequence-specific claims protect particular oligonucleotide compositions, making it difficult for competitors to develop identical or similar molecules without infringing.
References
- United States Patent and Trademark Office. (2016). US 9,283,214 B2. Retrieved from https://patents.google.com/patent/US9283214B2
- World Intellectual Property Organization. (2016). WO2016103957. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016103957
- European Patent Office. (2017). EP2977029. Retrieved from https://patents.google.com/patent/EP2977029A1
- Yamada, T., & Sumida, M. (2020). Antisense oligonucleotides for neurodegenerative diseases. Molecular Therapy. 28(7), 1749–1758.
